Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Test Type
1.1.1.1 Sample Type
1.1.1.1 Collection Site
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective – 1
1.4.2 Objective – 2
1.4.3 Objective – 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Gvr’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Test Type and Sample Type Snapshot
2.3 Collection Site Snapshot
2.4 Competitive Snapshot
Chapter 3 Cellular Health Screening Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rise in the adoption of telomere performance programs to lead a healthy life
3.3.1.2 Increase in importance of health-adjusted life expectancy (HALE)
3.3.1.3 Increasing government focus on preventive healthcare
3.3.1.4 Rise in geriatric population leading to growth in the need for cellular health screening
3.3.1.5 Increase in research activities
3.3.1.5 Growth in the adoption of direct-to-consumer approach for the availability of kits
3.3.1.7 Rise in burden of chronic diseases
3.3.2 Market restraint analysis
3.3.2.1 Problems associated with the transport of samples
3.3.2.2 Differences in the cost of test kits offered by different companies
3.3.3 Industry challenges
3.4 Cellular Health Screening Market Analysis Tools
3.4.1 Industry analysis – Porter’s
3.4.2 PESTLE Analysis
Chapter 4 Cellular Health Screening Market – Segment Analysis, By Test Type, 2018 – 2030 (USD Million)
4.1 Cellular Health Screening Market: Test Type Movement Analysis
4.2 Single Test Panels
4.2.1 Single test panels market estimates and forecast, 2018 – 2030 (USD Million)
4.2.2 Telomere Tests
4.2.2.1 Telomere test market estimates and forecast, 2018 – 2030 (USD Million)
4.2.3 Oxidative Stress Tests
4.2.3.1 Oxidative stress test market estimates and forecast, 2018 – 2030 (USD Million)
4.2.4 Inflammation Tests
4.2.4.1 Inflammation test market estimates and forecast, 2018 – 2030 (USD Million)
4.2.5 Heavy Metals Tests
4.2.5.1 Heavy metals test market estimates and forecast, 2018 – 2030 (USD Million)
4.3 Multi-test Panels
4.3.1 Multi-test panels market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 5 Cellular Health Screening Market – Segment Analysis, By Sample Type, 2018 – 2030 (USD Million)
5.1 Cellular Health Screening Market: Sample Type Movement Analysis
5.2 Blood
5.2.1 Blood market estimates and forecast, 2018 – 2030 (USD Million)
5.3 Saliva
5.3.1 Saliva market estimates and forecast, 2018 – 2030 (USD Million)
5.4 Serum
5.4.1 Serum market estimates and forecast, 2018 – 2030 (USD Million)
5.5 Urine
5.5.1 Urine market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 6 Cellular Health Screening Market – Segment Analysis, By Collection Site, 2018 – 2030 (USD Million)
6.1 Cellular Health Screening Market: Collection Site Movement Analysis
6.2 Home
6.2.1 Home market estimates and forecast, 2018 – 2030 (USD Million)
6.3 Office
6.3.1 Office market estimates and forecast, 2018 – 2030 (USD Million)
6.4 Hospital
6.4.1 Hospital market estimates and forecast, 2018 – 2030 (USD Million)
6.5 Diagnostic Labs
6.5.1 Diagnostic labs market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 7 Cellular Health Screening Market – Segment Analysis, By Region, 2018 – 2030 (USD Million)
7.1 Regional Market Snapshot
7.1.1 North America
7.1.1.1 North America cellular health screening market estimates and forecast, 2018-2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.2.2 Key country dynamics
7.1.1.2.3 Disease prevalence
7.1.1.2.4 Regulatory framework
7.1.1.2.5 Competitive scenario
7.1.1.3 Canada
7.1.1.3.1 Canada cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.3.2 Key country dynamics
7.1.1.3.3 Disease prevalence
7.1.1.3.4 Regulatory framework
7.1.1.3.5 Competitive scenario
7.1.2 Europe
7.1.2.1 Europe cellular health screening market estimates and forecast, 2018-2030 (USD Million)
7.1.2.2 UK
7.1.2.2.1 UK cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.2.2 Key country dynamics
7.1.2.2.3 Disease prevalence
7.1.2.2.4 Regulatory framework
7.1.2.2.5 Competitive scenario
7.1.2.3 Germany
7.1.2.3.1 Germany cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.3.2 Key country dynamics
7.1.2.3.3 Disease prevalence
7.1.2.3.4 Regulatory framework
7.1.2.3.5 Competitive scenario
7.1.2.4 France
7.1.2.4.1 France cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.4.2 Key country dynamics
7.1.2.4.3 Disease prevalence
7.1.2.4.4 Regulatory framework
7.1.2.4.5 Competitive scenario
7.1.2.5 Italy
7.1.2.5.1 Italy cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.5.2 Key country dynamics
7.1.2.5.3 Disease prevalence
7.1.2.5.4 Regulatory framework
7.1.2.5.5 Competitive scenario
7.1.2.6 Spain
7.1.2.6.1 Spain cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.6.2 Key country dynamics
7.1.2.6.3 Disease prevalence
7.1.2.6.4 Regulatory framework
7.1.2.6.5 Competitive scenario
7.1.2.7 Denmark
7.1.2.7.1 Denmark cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.7.2 Key country dynamics
7.1.2.7.3 Disease prevalence
7.1.2.7.4 Regulatory framework
7.1.2.7.5 Competitive scenario
7.1.2.8 Sweden
7.1.2.8.1 Sweden cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.8.2 Key country dynamics
7.1.2.8.3 Disease prevalence
7.1.2.8.4 Regulatory framework
7.1.2.8.5 Competitive scenario
7.1.2.9 Norway
7.1.2.9.1 Norway cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.9.2 Key country dynamics
7.1.2.9.3 Disease prevalence
7.1.2.9.4 Regulatory framework
7.1.2.9.5 Competitive scenario
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific cellular health screening market estimates and forecast, 2018-2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.2.2 Key country dynamics
7.1.3.2.3 Disease prevalence
7.1.3.2.4 Regulatory framework
7.1.3.2.5 Competitive scenario
7.1.3.3 China
7.1.3.3.1 China cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3.2 Key country dynamics
7.1.3.3.3 Disease prevalence
7.1.3.3.4 Regulatory framework
7.1.3.3.5 Competitive scenario
7.1.3.4 India
7.1.3.4.1 India cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4.2 Key country dynamics
7.1.3.4.3 Disease prevalence
7.1.3.4.4 Regulatory framework
7.1.3.4.5 Competitive scenario
7.1.3.5 South Korea
7.1.3.5.1 South Korea cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.5.2 Key country dynamics
7.1.3.5.3 Disease prevalence
7.1.3.5.4 Regulatory framework
7.1.3.5.5 Competitive scenario
7.1.3.6 Australia
7.1.3.6.1 Australia cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.6.2 Key country dynamics
7.1.3.6.3 Disease prevalence
7.1.3.6.4 Regulatory framework
7.1.3.6.5 Competitive scenario
7.1.3.7 Thailand
7.1.3.7.1 Thailand cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.7.2 Key country dynamics
7.1.3.7.3 Disease prevalence
7.1.3.7.4 Regulatory framework
7.1.3.7.5 Competitive scenario
7.1.4 Latin America
7.1.4.1 Latin America cellular health screening market estimates and forecast, 2018-2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.2.2 Key country dynamics
7.1.4.2.3 Disease prevalence
7.1.4.2.4 Regulatory framework
7.1.4.2.5 Competitive scenario
7.1.4.3 Mexico
7.1.4.3.1 Mexico cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.3.2 Key country dynamics
7.1.4.3.3 Disease prevalence
7.1.4.3.4 Regulatory framework
7.1.4.3.5 Competitive scenario
7.1.4.4 Argentina
7.1.4.4.1 Argentina cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.4.2 Key country dynamics
7.1.4.4.3 Disease prevalence
7.1.4.4.4 Regulatory framework
7.1.4.4.5 Competitive scenario
7.1.5 MEA
7.1.5.1 MEA cellular health screening market estimates and forecast, 2018-2030 (USD Million)
7.1.5.2 South Africa
7.1.5.2.1 South Africa cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.2.2 Key country dynamics
7.1.5.2.3 Disease prevalence
7.1.5.2.4 Regulatory framework
7.1.5.2.5 Competitive scenario
7.1.5.3 Saudi Arabia
7.1.5.3.1 Saudi Arabia cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.3.2 Key country dynamics
7.1.5.3.3 Disease prevalence
7.1.5.3.4 Regulatory framework
7.1.5.3.5 Competitive scenario
7.1.5.4 UAE
7.1.5.4.1 UAE cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.4.2 Key country dynamics
7.1.5.4.3 Disease prevalence
7.1.5.4.4 Regulatory framework
7.1.5.4.5 Competitive scenario
7.1.5.5 Kuwait
7.1.5.5.1 Kuwait cellular health screening market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5.5.2 Key country dynamics
7.1.5.5.3 Disease prevalence
7.1.5.5.4 Regulatory framework
7.1.5.5.5 Competitive scenario
Chapter 8 COMPETITIVE LANDSCAPE
8.1 Company Categorization
8.2 Strategy Mapping
8.2.1 New product launch
8.2.2 Partnerships
8.2.3 Acquisition
8.2.4 Collaboration
8.3 Company Market Share Analysis, 2022
8.4 Company Profiles
8.4.1 Life Length
8.4.1.1 Company overview
8.4.1.2 Financial performance
8.4.1.3 Product benchmarking
8.4.1.4 Strategic initiatives
8.4.2 SpectraCell Laboratories, Inc.
8.4.2.1 Company overview
8.4.2.2 Financial performance
8.4.2.3 Product benchmarking
8.4.2.4 Strategic initiatives
8.4.3 RepeatDx
8.4.3.1 Company overview
8.4.3.2 Financial performance
8.4.3.3 Product benchmarking
8.4.3.4 Strategic initiatives
8.4.4 Cell Science Systems
8.4.4.1 Company overview
8.4.4.2 Financial performance
8.4.4.3 Product benchmarking
8.4.4.4 Strategic initiatives
8.4.5 Quest Diagnostics Incorporated
8.4.5.1 Company overview
8.4.5.2 Financial performance
8.4.5.3 Product benchmarking
8.4.5.4 Strategic initiatives
8.4.6 Laboratory Corporation of America Holdings
8.4.6.1 Company overview
8.4.6.2 Financial performance
8.4.6.3 Product benchmarking
8.4.6.4 Strategic initiatives
8.4.7 OPKO Health, Inc.
8.4.7.1 Company overview
8.4.7.2 Financial performance
8.4.7.3 Product benchmarking
8.4.7.4 Strategic initiatives
8.4.8 Genova Diagnostics (GDX)
8.4.8.1 Company overview
8.4.8.2 Financial performance
8.4.8.3 Product benchmarking
8.4.8.4 Strategic initiatives
8.4.9 Immundiagnostik AG
8.4.9.1 Company overview
8.4.9.2 Financial performance
8.4.9.3 Product benchmarking
8.4.9.4 Strategic initiatives
8.4.10 DNA Labs India
8.4.10.1 Company overview
8.4.10.2 Financial performance
8.4.10.3 Product benchmarking
8.4.10.4 Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/